THU555 Stress Induced AIPB Expression In Triple Negative (ER-/PR-/Her2-) Breast Tumors Reduces Estradiol

por Patrawala, Mahjabin, Bose, Himangshu S
Publicado 2023

Deep (phospho)proteomics profiling of pre- treatment needle biopsies identifies signatures of treatment resistance in HER2(+) breast cancer

por Debets, Donna O., Stecker, Kelly E., Piskopou, Anastasia, Liefaard, Marte C., Wesseling, Jelle, Sonke, Gabe S., Lips, Esther H., Altelaar, Maarten
Publicado 2023

YAP1 Expression in HR+HER2− Breast Cancer: 21-Gene Recurrence Score Analysis and Public Dataset Validation

por Park, Inho, Lee, Yangkyu, Kim, Jee Hung, Bae, Soong June, Ahn, Sung Gwe, Jeong, Joon, Cha, Yoon Jin
Publicado 2023

Dual-Targeted Therapy in HER2-Overexpressing Breast Cancer with Trastuzumab and Novel Cholesterol-Based Nioplexes Silencing Mcl-1

por Pengnam, Supusson, Opanasopit, Praneet, Rojanarata, Theerasak, Yingyongnarongkul, Boon-ek, Thongbamrer, Chopaka, Plianwong, Samarwadee
Publicado 2023

Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma

por Burger, Michael C, Forster, Marie-Therese, Romanski, Annette, Straßheimer, Florian, Macas, Jadranka, Zeiner, Pia S, Steidl, Eike, Herkt, Stefanie, Weber, Katharina J, Schupp, Jonathan, Lun, Jennifer H, Strecker, Maja I, Wlotzka, Karolin, Cakmak, Pinar, Opitz, Corinna, George, Rosemol, Mildenberger, Iris C, Nowakowska, Paulina, Zhang, Congcong, Röder, Jasmin, Müller, Elvira, Ihrig, Kristina, Langen, Karl-Josef, Rieger, Michael A, Herrmann, Eva, Bonig, Halvard, Harter, Patrick N, Reiss, Yvonne, Hattingen, Elke, Rödel, Franz, Plate, Karl H, Tonn, Torsten, Senft, Christian, Steinbach, Joachim P, Wels, Winfried S
Publicado 2023

Reassessing Estrogen Receptor Expression Thresholds for Breast Cancer Prognosis in HER2-negative Patients Using Shape Restricted Modeling

por Dong, Wenli, Fujii, Takeo, Ning, Jing, Iwase, Toshiaki, Qin, Jing, Ueno, Naoto T, Shen, Yu
Publicado 2023

Pertuzumab plus high-dose trastuzumab for HER2-positive breast cancer with brain metastases: PATRICIA final efficacy data

por Lin, Nancy U., Kumthekar, Priya, Sahebjam, Solmaz, Ibrahim, Nuhad, Fung, Anita, Cheng, Anna, Nicholas, Alan, Sussell, Jesse, Pegram, Mark
Publicado 2023

Response of Brain and Meningeal Metastases to Trastuzumab-Deruxtecan in a Patient with HER2-Low Breast Cancer: A Case Report

por Wolf, Benita, Dunet, Vincent, Dubruc, Estelle, Dolcan, Ana, Nicod Lalonde, Marie, Schiappacasse, Luis, Zaman, Khalil
Publicado 2023

Clinicopathologic Features and Prognosis of Female Early Breast Cancer With HER2 Low Expression: A Propensity Score Matched Analysis

por Dai, Lanyi, Huang, Qiyuan, Guo, Rong, Zhu, Keying, Tang, Yiyin, Chen, Dedian, Huang, Sheng
Publicado 2023

Development of High-Loading Trastuzumab PLGA Nanoparticles: A Powerful Tool Against HER2 Positive Breast Cancer Cells

por Caputo, Tania Mariastella, Barisciano, Giovannina, Mulè, Chiara, Cusano, Angela Maria, Aliberti, Anna, Muccillo, Livio, Colantuoni, Vittorio, Sabatino, Lina, Cusano, Andrea
Publicado 2023

Are We Prepared for the CDK4/6 Revolution With HR+/HER2− Breast Cancers?: The Importance of Patient Adherence to Adjuvant Therapies

por Azoz, Seyla, Peters, Martin, Jones, Graham
Publicado 2023

Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy

por Munzone, Elisabetta, Curigliano, Giuseppe, Rocca, Andrea, Bonizzi, Giuseppina, Renne, Giuseppe, Goldhirsch, Aron, Nolè, Franco
Publicado 2006

Combined Allogeneic Tumor Cell Vaccination and Systemic Interleukin 12 Prevents Mammary Carcinogenesis in HER-2/neu Transgenic Mice

por Nanni, Patrizia, Nicoletti, Giordano, De Giovanni, Carla, Landuzzi, Lorena, Di Carlo, Emma, Cavallo, Federica, Pupa, Serenella M., Rossi, Ilaria, Colombo, Mario P., Ricci, Cinzia, Astolfi, Annalisa, Musiani, Piero, Forni, Guido, Lollini, Pier-Luigi
Publicado 2001

A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours

por Attard, G, Kitzen, J, Blagden, S P, Fong, P C, Pronk, L C, Zhi, J, Zugmaier, G, Verweij, J, de Bono, J S, de Jonge, M
Publicado 2007

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease

por Zidan, J, Dashkovsky, I, Stayerman, C, Basher, W, Cozacov, C, Hadary, A
Publicado 2005

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer

por Burcombe, R J, Makris, A, Richman, P I, Daley, F M, Noble, S, Pittam, M, Wright, D, Allen, S A, Dove, J, Wilson, G D
Publicado 2005

Peptide HER2(776–788) represents a naturally processed broad MHC class II-restricted T cell epitope

por Sotiriadou, R, Perez, S A, Gritzapis, A D, Sotiropoulou, P A, Echner, H, Heinzel, S, Mamalaki, A, Pawelec, G, Voelter, W, Baxevanis, C N, Papamichail, M
Publicado 2001

Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer

por Gori, S, Colozza, M, Mosconi, A M, Franceschi, E, Basurto, C, Cherubini, R, Sidoni, A, Rulli, A, Bisacci, C, Angelis, V De, Crinò, L, Tonato, M
Publicado 2004

Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients

por Liang, Zhiyong, Zeng, Xuan, Gao, Jie, Wu, Shafei, Wang, Peng, Shi, Xiaohua, Zhang, Jing, Liu, Tonghua
Publicado 2008

HER-2/neu amplification testing in breast cancer by Multiplex Ligation-dependent Probe Amplification: influence of manual- and laser microdissection

por Moelans, Cathy B, de Weger, Roel A, Ezendam, Chantal, van Diest, Paul J
Publicado 2009